AtriCure Announces Angie Wirick as Chief Financial Officer
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons
Business Wire · 08/06 20:00
AtriCure Inc. (ATRC): Were Hedge Funds Right About Buying This Stock?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 08/03 12:55
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time-to-time in AtriCure's SEC filings. AtriCure's results may differ materially from tho
Motley Fool · 07/29 09:01
More on AtriCure Q2 earnings
Seeking Alpha · 07/29 04:00
Recap: AtriCure Q2 Earnings
Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 123.53% over the past year to ($0.38), which beat the estimate of ($0.61).Revenue of $40,824,000 decreased by 30.
Benzinga · 07/28 20:22
AtriCure EPS beats by $0.16, beats on revenue
Seeking Alpha · 07/28 20:07
AtriCure Reports Second Quarter 2020 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.